Depression and fatigue are common in people with MS. While fatigue results from MS-related chronic inflammation and neuronal damage, depression is caused by psychological and social factors that may not be directly related to multiple sclerosis.
Both depression and fatigue may be managed through mindfulness-based interventions, which are designed to boost mental well-being by purposefully staying present in the moment and acknowledging one’s feelings in an honest but nonjudgmental way. Trait mindfulness is defined as a permanent state of paying attention to the present moment in all aspects of life.
Hypothesizing that depression mediates the association between mindfulness and fatigue, a team of German researchers now explored the relationship between trait mindfulness, depression, and fatigue in MS patients.
Click here to subscribe to the Multiple Sclerosis News Today Newsletter! 5 (2)
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Treatment with Tysabri (natalizumab) can improve mental and social health in people with multiple sclerosis (MS), according to new data presented at the 2021 virtual American Academy of Neurology annual meeting (AANAM).
Data presented at AANAM also indicate that less frequent dosing of Tysabri can reduce the risk of rare brain infections, while still lowering MS disease activity.
Tysabri, by Biogen, is an approved treatment for relapsing forms of MS, and works by blocking inflammatory immune cells from getting into the brain. In clinical trials, Tysabri has been demonstrated to lower the rate of MS relapses and to ease symptoms. Treatment with Tysabri also has been associated wi
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
When the weather is unusually warm, people with multiple sclerosis (MS) are more likely to require emergency medical care, new research shows.
The findings indicate that people with health conditions like MS may be at increased risk of health problems as temperatures rise due to climate change, according to Holly Elser, PhD, an epidemiologist and medical student at Stanford University.
The idea for this study, according to Elser, originated with a MS patient during a routine medical appointment: “[the patient] mentioned off-handedly, ‘you know, my MS gets really bad when it’s hot outside, ” said Elser.
#AANAM – COVID-19 Often Leads to Flares in MS Patients, Survey Finds multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Ublituximab, an investigational therapy for relapsing forms of multiple sclerosis (MS), significantly outperformed Aubagio (teriflunomide) at reducing patients’ annualized relapse rates and lowering the number of brain lesions over nearly two years, according to data from the ULTIMATE clinical trials.
“The results of the ULTIMATE I and II studies show that not only did ublituximab effectively reduce relapses in patients with RMS, but had a profound effect on suppressing inflammatory activity,” Steinman, the global study chair for the two trials, said in a press release.